T cell activation via antigen-presenting cell stimulation (TCR (when referring specifically to the receptor; no abbreviation for the entire activation process))

The interaction between **T cells** and **antigen-presenting cells (APCs)** is the centerpiece of adaptive immunity. Activation requires two signals: *Signal 1* via TCR recognition of antigenic peptides presented by *major histocompatibility complex (MHC)* molecules on the APC and *Signal 2* delivered by costimulatory proteins (most notably the B7 family, CD80/CD86, interacting with CD28 on T cells)[1][3][5][7]. Without both signals, T cells either fail to activate or become anergic (unresponsive), which helps maintain immune tolerance[3][5]. Activated pathways include protein tyrosine kinase cascades, MAP kinase signaling, and transcription factor activation (NFAT, NF-κB, AP-1)[2][4][6][8][10]. Pharmacological intervention targets key molecules in this interface to modulate immune responses for cancer, autoimmunity, and transplantation. Despite its centrality to immunology, "T cell activation via antigen-presenting cell stimulation" is a process and not a single targetable biomolecule. A more precise target for structured data would be the **T cell antigen receptor (TCR) complex** or specific co-stimulatory molecules (e.g., CD28, CTLA-4)[2][3]. The name given in the query is too broad and refers to a cellular mechanism rather than a canonical drug target.

Other names

TCR-MHC interactionImmunological synapse formationT cell activation cascade

Blockade or enhancement of TCR signaling; Modulation of co-stimulatory pathways (CD28/B7, CTLA-4); Inhibition of signaling cascades (calcineurin inhibition blocks NFAT activation)